Evidence map›Paper›PMID 40766177›Full record

ArticleFrontiers in aging neuroscience2025

miR-423-5p and miR-92a-3p in Alzheimer's disease: relationship with pathology and cognition.

Sang-Won Han, Young Ho Park, Jung-Min Pyun, Paula J Bice, SangYun Kim, Andrew J Saykin, Kwangsik Nho

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sang-Won HanDepartment of Neurology, Soonchunhyang University Seoul Hospital and Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
Young Ho ParkDepartment of Neurology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam-si, Republic of Korea.
Jung-Min PyunDepartment of Neurology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam-si, Republic of Korea.
Paula J BiceDepartment of Radiology and Imaging Sciences, Center for Computational Biology and Bioinformatics, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, United States.
SangYun KimDepartment of Neurology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam-si, Republic of Korea.
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Center for Computational Biology and Bioinformatics, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, United States.
Kwangsik NhoDepartment of Radiology and Imaging Sciences, Center for Computational Biology and Bioinformatics, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, United States.

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo, NILUFER ERTEKIN-TANER · 2023 to 2026
$42.0M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
KBASE2: Korean Brain Aging Study, Longitudinal Endophenotypes and Systems BiologyU01AG072177 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LEE, DONG YOUNG, NHO, KWANGSIK TIMOTHY · 2021 to 2025
$11.2M
MicroRNAs as Diagnostic and Prognostic Biomarker of Alzheimer's DiseaseRF1AG078299 · NIA · RHODE ISLAND HOSPITAL · PI BLUSZTAJN, JAN KRZYSZTOF, DELALLE, IVANA · 2022 to 2022
$2.4M
Long Non-coding RNAs as Therapeutic Targets and Biomarkers of Alzheimer's Disease and Related DementiasR01AG084624 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JAN Krzysztof BLUSZTAJN, IVANA DELALLE · 2024 to 2026
$2.3M
Neurobiological Role of MicroRNA in Alzheimer'sR56AG051086 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHIRI, DEBOMOY K · 2023 to 2023
$627k
NIA NIH HHS P30 AG072976NIA NIH HHS R01 AG084624NIA NIH HHS R56 AG051086NIA NIH HHS RF1 AG078299NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG072177NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG074879
6 · The paper itself

Abstract

Background: MicroRNAs (miRNAs), small and highly conserved non-coding RNA molecules, have emerged as promising molecular biomarkers due to their regulatory roles in gene expression and stability in blood. Methods: We used measurements of 64 plasma miRNAs from 145 participants in the Alzheimer's disease Neuroimaging Initiative cohort, including 74 probable AD patients and 71 cognitively normal (CN) older adults. We performed principal component analysis (PCA) with factor rotation for dimension reduction to identify AD-associated principal components (PCs) and their key miRNAs with factor loadings higher than 0.8. We investigated their association with amyloid/tau/neurodegeneration (A/T/N) biomarkers and cognition. After identifying the candidate target genes of key miRNAs, we performed pathway enrichment analysis. We conducted mediation analyses to assess the effect of the associations between miRNAs and A/T/N biomarkers on AD diagnosis and cognition. Finally, we used a machine learning approach to evaluate the performance of key miRNAs for AD classification. Results: PCA identified one PC as significantly associated with AD. The PC was also significantly associated with CSF p-tau levels, hippocampal volume, and cognition. Two key miRNAs (miR-423-5p and miR-92a-3p) in the PC were associated with AD. Lower levels of miR-423-5p and miR-92a-3p were associated with reduced hippocampal volume and worse cognition, and lower levels of miR-423-5p were associated with higher brain amyloid deposition. Pathway enrichment analysis identified several significant biological processes, including memory, protein phosphorylation, and the phosphatidylinositol-3-phosphate biosynthetic process. Mediation analysis revealed that miR-423-5p, but not miR-92a-3p, had indirect effects on AD diagnosis and memory performance through brain amyloid deposition and brain atrophy. Machine learning analysis demonstrated that incorporating two key miRNAs improved the performance of demographic information for AD classification. Conclusion: Plasma miR-423-5p and miR-92a-3p are implicated in AD pathology and cognitive decline, providing insights into their roles in disease mechanisms. This study suggests the potential of these miRNAs as blood-based molecular biomarkers for AD.

Indexed as

Alzheimer’s diseasecognitive declinemachine learningMicroRNAsmiR-423-5pmiR-92a-3p

Identifiers

PMID40766177
PMCPMC12321855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.